Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 33

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 33
---
  Trading of industrial chemicals  Investment holding  Total   Three month period ended June 30, 2025              REVENUE $3,466  $2,256,787  $-  $2,260,253                  COST OF REVENUE  (2,725)  (1,889,506)  -   (1,892,231)                 GROSS PROFIT  741   367,281   -   368,022                  OTHER INCOME                Dividend income   -   8,626   -   8,626 Interest income  25,092   4,676   -   29,768 Fair value gain on investments in equity securities  -   23,742   -   23,742 Reversal of expected credit losses  -   69,759   -   69,759 Others  3,477   74,089   -   77,566 TOTAL OTHER INCOME  28,569   180,892   -   209,461                  OPERATING EXPENSES                Sales and marketing  (28,424)  (559,541)  (20,462)  (608,427)Research and development  (12,557)  -   -   (12,557)General and administrative  (149,164)  (161,591)  (206,035)  (516,790)Fair value loss on investments in equity securities  -   (51,002)  -   (51,002)TOTAL OPERATING EXPENSES  (190,145)  (772,134)  (226,497)  (1,188,776)                 LOSS FROM OPERATIONS  (160,835)  (223,961)  (226,497)  (611,293)                 FINANCE COSTS  (3,273)  (1,599)  (7)  (4,879)                 LOSS BEFORE TAX  (164,108)  (225,560)